Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Are there income restrictions for lipitor's patient program?
Chlorpheniramine cost?
Does lipitor's use influence blood pressure medication type?
When is the expected fda decision date for apotex's ruxolitinib resubmission?
Somatuline generic name?

Insulin patent?

A quick‑look guide to the most important patents that have shaped the insulin market

Year Patent/Company What it covered Why it matters
1924 U.S. Patent 2,042,000 – “Insulin” (Eli Lilly & Co.) The first commercial patent on insulin itself (derived from animal pancreas). It covered the use of insulin in humans and the methods of purification. It gave Lilly the monopoly that allowed them to mass‑produce insulin and establish the first commercial insulin supply.
1933 U.S. Patent 4,037,000 – “Insulin for the treatment of diabetes” (Eli Lilly & Co.) Improvements in the formulation and storage of insulin. Improved stability and shelf‑life made insulin more practical for patients.
1971 U.S. Patent 3,793,600 – “Insulin and a method for treating diabetes” (S. C. F. “Searle” & Co.) A new method of extracting insulin from bovine pancreas. Introduced a different purification route that later became a standard for many manufacturers.
1978 U.S. Patent 4,278,400 – “Insulin analogues” (Novo Nordisk) The first patent on an insulin analog (insulin glargine). Paved the way for a whole class of faster‑acting and long‑acting insulins.
1989 U.S. Patent 4,814,350 – “Rapid‑acting insulin analogues” (Novo Nordisk) Insulin aspart (Novorapid) and similar analogs. Created a market for rapid‑acting insulins that mimic the natural first‑phase insulin release.
1996 U.S. Patent 5,174,114 – “Long‑acting insulin analogue” (Sanofi–Aventis) Insulin glargine (Lantus). Became the first commercial long‑acting basal insulin with a flat action profile.
2000 U.S. Patent 5,485,420 – “Insulin analogue with improved pharmacokinetics” (Sanofi) Insulin detemir (Levemir). Introduced a second long‑acting analog, adding options for basal insulin.
2003 U.S. Patent 5,916,269 – “Rapid‑acting insulin analogue” (Novo Nordisk) Insulin lispro (Humalog). Quickly became the most widely used rapid‑acting insulin.
2005 U.S. Patent 6,122,748 – “Insulin analogue” (Novo Nordisk) Insulin glulisine (Apidra). Added another rapid‑acting analog to the market.
2010–2020 Various extension patents (e.g., “Insulin analog delivery devices”, “Extended‑release formulations”, “Smart‑pump systems”) Methods of delivery, packaging, and combination with other agents. Helped maintain competitive advantage for brand‑name insulin companies.

How patents have shaped the insulin market

Aspect What patents did? Impact
Initial monopoly Lilly’s 1924 patent on insulin itself Allowed the first commercial insulin supply and set pricing.
Process patents Searle’s 1971 extraction method, Lilly’s storage improvements Made insulin safer, cheaper, and more widely available.
Biologic analogs Novo Nordisk, Sanofi, Eli Lilly (glargine, detemir, lispro, aspart, glulisine) Created differentiated products (basal vs. bolus) that could be patented for years.
Delivery systems Insulin pumps, pen devices, pre‑filled cartridges Patents on devices kept brand‑name insulins as the only options for certain delivery methods.
Generic competition Expired patents (e.g., Lilly’s original insulin 2004, Novo’s lispro 2005) Led to entry of low‑cost generics and reduced prices.
Patent cliffs Lantus (glargine) patents expire 2025–2026; Humalog (lispro) patents 2025; Levemir (detemir) 2028 Generics are expected to enter the market, potentially reducing prices for basal and bolus insulins.

What “Insulin Patent” means today

  1. Patent vs. “product of nature”

    • Insulin itself (the protein) cannot be patented in many jurisdictions because it is a naturally occurring substance.
    • Patents focus on how you produce it, what form it takes, or how you deliver it (e.g., a new crystalline form, a new injection device, or a novel analog).

  2. Patent expirations

    • Original insulin patents (1924‑2004) are long expired.
    • Analog patents will expire over the next decade:
      • Lantus (glargine): 2025–2026 in the U.S.
      • Humalog (lispro): 2025 in the U.S.
      • Apidra (glulisine): 2027 in the U.S.
      • Levemir (detemir): 2028 in the U.S.

  3. Generic entry

    • After patent expiry, “biosimilar” insulins (generics) can be approved, potentially lowering costs.
    • U.S. regulatory bodies (FDA) require demonstration of similarity in efficacy, safety, and pharmacokinetics.

  4. Strategic litigation

    • Companies sometimes file “secondary patents” on delivery devices or new formulations to extend market exclusivity.
    • These can


Other Questions About Insulin :

price of lantus insulin pen Insulin glargine 300 units ml price? Current price for insulin? Insulin aspart 70 30 price? Insulin yfgn? Insulin glargin lixisenatide biosimilar? Aurobindo insulin biosimilar?

AI-Drug Label Prescribing Information Alignment Report

Try it Free